Bio-Bridge-Science Inc. CEO Dr. Liang Qiao Featured in CEOcast Interview
March 09 2006 - 12:26PM
Business Wire
Bio-Bridge-Science Inc. (OTCBB:BGES) announced that CEO Dr. Liang
Qiao is featured in an interview with CEOcast. The topics of
discussion include the company's unique technology platform and its
promising new HIV vaccine. Dr. Qiao also elaborates upon Bio-Bridge
Science's plans and prospects for the upcoming year. The interview
is available through CEOcast and can now be heard at
www.ceocast.com in the latest interviews section. About Bio-Bridge
Science: Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is
expected to enter clinical trials this year in China. The vaccine,
based on exclusive technology co-developed by CEO Liang Qiao, an
associate professor at Loyola University Chicago's Strich School of
Medicine, targets infection in mucosal tissues, the first type of
tissue attacked by HIV. The Chinese government, mindful of the
rapid expansion of AIDS in China has, through the "Green Mile
Policy" acted to expedite the approval of domestically produced HIV
Vaccines and has dramatically increased its spending on
AIDS-related research. In accordance with this policy, Bio-Bridge
expects to bring its therapeutic HIV Vaccine to market as early as
2008, far in advance of many other HIV Vaccines currently in
development. Bio-Bridge is currently constructing a new $3 million
state-of-the-art GMP research and manufacturing facility in
Beijing, which is expected to be completed by mid-year.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024